These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

311 related items for PubMed ID: 23241227

  • 1. Comparison of Ranibizumab monotherapy versus combination of Ranibizumab with photodynamic therapy with neovascular age-related macular degeneration.
    Krebs I, Vécsei Marlovits V, Bodenstorfer J, Glittenberg C, Ansari Shahrezaei S, Ristl R, Binder S.
    Acta Ophthalmol; 2013 May; 91(3):e178-83. PubMed ID: 23241227
    [Abstract] [Full Text] [Related]

  • 2. Ranibizumab monotherapy versus single-session verteporfin photodynamic therapy combined with as-needed ranibizumab treatment for the management of neovascular age-related macular degeneration.
    Bashshur ZF, Schakal AR, El-Mollayess GM, Arafat S, Jaafar D, Salti HI.
    Retina; 2011 Apr; 31(4):636-44. PubMed ID: 21124254
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Combination treatment of photodynamic therapy with verteporfin and intravitreal ranibizumab in patients with retinal angiomatous proliferation.
    Seidel G, Werner C, Weger M, Steinbrugger I, Haas A.
    Acta Ophthalmol; 2013 Sep; 91(6):e482-5. PubMed ID: 23786546
    [Abstract] [Full Text] [Related]

  • 5. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results.
    Larsen M, Schmidt-Erfurth U, Lanzetta P, Wolf S, Simader C, Tokaji E, Pilz S, Weisberger A, MONT BLANC Study Group.
    Ophthalmology; 2012 May; 119(5):992-1000. PubMed ID: 22424834
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Triple therapy for anti-vascular endothelial growth factor nonresponders in neovascular age-related macular degeneration: impact of different photodynamic therapy parameters.
    Veritti D, Lanzetta P.
    Ophthalmologica; 2013 May; 230(3):131-7. PubMed ID: 23948986
    [Abstract] [Full Text] [Related]

  • 8. Prospective comparison of low-fluence photodynamic therapy combined with intravitreal bevacizumab versus bevacizumab monotherapy for choroidal neovascularization in age-related macular degeneration.
    Datseris I, Kontadakis GA, Diamanti R, Datseris I, Pallikaris IG, Theodossiadis P, Tsilimbaris MK.
    Semin Ophthalmol; 2015 Mar; 30(2):112-7. PubMed ID: 24117412
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years.
    Spielberg L, Leys A.
    Graefes Arch Clin Exp Ophthalmol; 2010 Jul; 248(7):943-56. PubMed ID: 20204659
    [Abstract] [Full Text] [Related]

  • 11. A randomised prospective double-masked exploratory study comparing combination photodynamic treatment and intravitreal ranibizumab vs intravitreal ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration.
    Vallance JH, Johnson B, Majid MA, Banerjee S, Mandal K, Bailey CC.
    Eye (Lond); 2010 Oct; 24(10):1561-7. PubMed ID: 20577273
    [Abstract] [Full Text] [Related]

  • 12. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.
    Kodjikian L, Souied EH, Mimoun G, Mauget-Faÿsse M, Behar-Cohen F, Decullier E, Huot L, Aulagner G, GEFAL Study Group.
    Ophthalmology; 2013 Nov; 120(11):2300-9. PubMed ID: 23916488
    [Abstract] [Full Text] [Related]

  • 13. Intravitreal bevacizumab alone versus in combination with photodynamic therapy for the treatment of neovascular maculopathy in patients aged 50 years or older: 1-year results of a prospective clinical study.
    Lim JY, Lee SY, Kim JG, Lee JY, Chung H, Yoon YH.
    Acta Ophthalmol; 2012 Feb; 90(1):61-7. PubMed ID: 20337606
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.
    Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T, ANCHOR Study Group.
    Ophthalmology; 2009 Jan; 116(1):57-65.e5. PubMed ID: 19118696
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Intraretinal cysts are the most relevant prognostic biomarker in neovascular age-related macular degeneration independent of the therapeutic strategy.
    Ritter M, Simader C, Bolz M, Deák GG, Mayr-Sponer U, Sayegh R, Kundi M, Schmidt-Erfurth UM.
    Br J Ophthalmol; 2014 Dec; 98(12):1629-35. PubMed ID: 25079064
    [Abstract] [Full Text] [Related]

  • 18. Intravitreal ranibizumab and bevacizumab in combination with full-fluence verteporfin therapy and dexamethasone for exudative age-related macular degeneration.
    Forte R, Bonavolontà P, Benayoun Y, Adenis JP, Robert PY.
    Ophthalmic Res; 2011 Dec; 45(3):129-34. PubMed ID: 20847575
    [Abstract] [Full Text] [Related]

  • 19. INITIAL VERSUS DELAYED PHOTODYNAMIC THERAPY IN COMBINATION WITH RANIBIZUMAB FOR TREATMENT OF POLYPOIDAL CHOROIDAL VASCULOPATHY: The Fujisan Study.
    Gomi F, Oshima Y, Mori R, Kano M, Saito M, Yamashita A, Iwata E, Maruko R, Fujisan Study Group.
    Retina; 2015 Aug; 35(8):1569-76. PubMed ID: 25830698
    [Abstract] [Full Text] [Related]

  • 20. Anti-vascular endothelial growth factor monotherapy versus combination treatment with photodynamic therapy for subfoveal choroidal neovascularization secondary to causes other than age-related macular degeneration.
    Chen L, Miller JW, Vavvas D, Kim IK.
    Retina; 2011 Nov; 31(10):2078-83. PubMed ID: 21691258
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.